Bharat Biotech concludes phase 3 Covaxin trial, claims 77.8% efficacy against COVID 19

Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it to be 77.8 per cent effective against COVID-19. It also added that Covaxin gives 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant.

from IndiaTV: Google News Feed https://ift.tt/3yjjB2J